Clinical Trial Diversity: Data Points to Structural, Not Patient-Specific Solutions
Executive Summary
Minorities are more likely to participate in cancer clinical trials than white people, but they are less likely to get the chance to say yes, highlighting the importance of bringing studies to different locations if sponsors are to be successful at increasing diversity.
You may also be interested in...
How We Can Use the FDA’s 2022 Diversity Guidance to Make Our Clinical Trials More Inclusive
Catherine Gregor is the chief clinical trial officer at Florence Healthcare, a leading provider of clinical trial software that helps researchers collaborate and manage workflows and information. Based on her extensive experience in clinical research administration, Gregor explains how the recent US FDA guidance on diversity and inclusion in clinical trials represents a critical opportunity to make clinical research more inclusive and equitable.
US FDA’s Woodcock Sees Clinical Trial Reform Coming, But ‘Not Wholly Optimistic’
Acting FDA commissioner says there are a lot of strong forces in the research and pharma industries that could curb efforts to make pandemic-related clinical trial reforms permanent.
How Do You Build A Clinical Trial Network Focused On Diversity?
Stakeholders discuss network models, barriers to their creation, and what is needed for them to be successful at PhRMA meeting.